ライフサイエンスコーパス: combination therapy

1 h monotherapy, and 35.5 letters for PCV with combination therapy).

2 ajor active anticancer ingredient for DSF/Cu combination therapy.

3 ies can resemble the effects of a concurrent combination therapy.

4 of HNSCC to tocilizumab (TCZ) and cisplatin combination therapy.

5 AR T cells and oncolytic viruses to optimize combination therapy.

6 Fluoroquinolones were only given as part of combination therapy.

7 trapolated to individuals with asthma taking combination therapy.

8 Analyses were done on patients who received combination therapy.

9 argets for treatment, and the use of initial combination therapy.

10 of the positive physiological effect of the combination therapy.

11 creases spine and hip BMD more than standard combination therapy.

12 of a three-component direct-acting antiviral combination therapy.

13 reased significantly in primary tumors after combination therapy.

14 l artesunate followed by an oral artemisinin-combination therapy.

15 ardiac defibrillator+optimal pharmacological combination therapy.

16 mising agents for autophagy inhibition-based combination therapy.

17 are required for tumor regression following combination therapy.

18 proximal cascade, providing a blueprint for combination therapy.

19 of cancer and a rational basis for targeted combination therapy.

20 s, offering a safe and economic strategy for combination therapy.

21 fy patients for therapy or as a target in a (combination) therapy.

22 c reprogramming that can be targeted by drug combination therapies.

23 CD39, including their inclusion in rational combination therapies.

24 is (TB) and co-morbidities involve multidrug combination therapies.

25 resistance management based on mixtures and combination therapies.

26 of MEKi resistance provided a rationale for combination therapies.

27 e to optimize ICB response and to design new combination therapies.

28 ich resulted in increase in survival in both combination therapies.

29 es by helping physicians select anti-TNF and combination therapies.

30 reatment warrant the need to adapt resilient combination therapies.

31 operties, early clinical data, and potential combination therapies.

32 dex, overcome drug resistance, and establish combination therapies.

33 modulation and may enable the development of combination therapies.

34 ng new insights into development of rational combination therapies.

35 bodies, antibody drug conjugates (ADCs), and combination therapies.

36 patients with AML receiving venetoclax-based combination therapies.

37 escences and protect the future of ART-based combination therapies.

38 ient selection and future development of new combination therapies.

39 anti-IL-2 antibodies have been developed for combination therapies.

40 ing new immune checkpoint blockade (ICB) and combination therapies.

41 urther preclinical studies for ERBB and PI3K combination therapies.

42 ogical connection that could be exploited in combination therapies.

43 ified potential drug targets for chloroquine combination therapies.

44 taxane, are still in need of more effective combination therapies.

45 fety, and tolerability of triple artemisinin combination therapies.

46 g of therapeutic agents and facilitating new combination therapies.

47 ty to establish exclusion criteria for ideal combination therapies.

48 tumors, was exposed to 21 monotherapies and combination therapies.

49 tigate whether outcomes can be improved with combination therapies.

50 ne transport inhibitors (PTIs) to be used in combination therapies.

51 associated with the identification of novel combination therapies.

52 clines highlights the potential of NR-160 in combination therapies.

53 t arms (colistin monotherapy 6/128 [4.7%] vs combination therapy 12/121 [9.9%]; P = .111).

54 us patients randomized to colistin-meropenem combination therapy (12/108, 11.1%; P = .669).

55 In phase 2, patients treated with combination therapy achieved an overall response rate of

56 Artemisinin-based combination therapy (ACT) is recommended for uncomplicat

57 Artemisin combination therapy (ACT) is the main treatment option f

58 al radical cure, combining artemisinin-based combination therapy (ACT) with a hypnozoitocidal antimal

59 Artemisinin-based combination therapies (ACTs) have demonstrated in vitro

60 e (PQ) in combination with artemisinin-based combination therapies (ACTs) in areas of low transmissio

61 th being seen at a facility with Artemisinin Combination Therapies (ACTs) in stock (adjusted OR 1.60;

62 Ultimately, combination therapies addressing multiple aspects of NAS

63 n plus ATR inhibition may be a promising new combination therapy against cancer.

64 upting this pathway, we develop an effective combination therapy against chemosurvival.

65 decision to choose multiple antibiotics for combination therapy against drug resistant bacteria can

66 investigate DTCs in bone marrow and identify combination therapy against metabolic and kinase targets

67 inhibitor sensitivity and uncover potential combination therapies and biomarkers for patient selecti

68 bitors and discuss the potential of emerging combination therapies and biomarkers of response.

69 e therapeutic potential of anticancer drugs, combination therapies and multitarget drugs have been su

70 of resistance necessitates investigation of combination therapies and their effects on tumor evoluti

71 e primary end point was met by 59 (35%) with combination therapy and 68 (39%) with standard therapy (

72 We review the rationale for combination therapy and different strategies, including

73 he clinical development of HSP90(i) + MEK(i) combination therapy and highlight the power of clinicall

74 n and black groups intensified to noninsulin combination therapy and insulin therapy more slowly than

75 as endoscopic ultrasound-guided glue-coiling combination therapy and the emergence of highly effectiv

76 ted the effectiveness of the BBB-penetrating combination therapy and the macrophage-mediated innate i

77 eeks of the study and throughout 48 weeks of combination therapy and virologic control (HBsAg positiv

78 therapeutic efficacy, IL-15 will be used in combination therapy, and combination trials with checkpo

79 n monotherapy, intensification to noninsulin combination therapy, and intensification to insulin ther

80 cedural approach, "leave nothing behind" or "combination therapy," and vessel size.

81 ; (2) anti-tumor necrosis factor agents; (3) combination therapy; and (4) no treatment with immunosup

82 photericin B, voriconazole, caspofungin, and combination therapy; and third-party payer and societal

83 atment of such problematic infections is the combination therapy "antibiotic + inhibitor of resistanc

84 sient or incomplete, suggesting a need for a combination therapy approach.

85 nce to ICIs has focused research towards new combination therapy approaches that seek to increase res

86 Owing to the high expression levels of HER2, combination therapies are currently required for the tre

87 Most combination therapies are developed based on targets of

88 Efficacious combination therapies are thus needed to block drug-tole

89 s controlling energy balance has highlighted combination therapies as a promising strategy to enhance

90 r new antiviral agents and the necessity for combination therapies as has been shown to be beneficial

91 ximum walking distance significantly favored combination therapy at 1-year follow-up, the difference

92 Combination therapy based on nanomedicine has gained mom

93 e identified patients likely to benefit from combination therapy, but vorinostat did not change ER ex

94 diotherapy have had their widespread role in combination therapy called into question.

95 The model also showed that combination therapies can delay the onset of resistance

96 anistic insights from spatial cellular maps, combination therapy can efficiently eliminate cancers wi

97 This novel combination therapy can improve the effects of magnetic

98 Triple artemisinin-based combination therapies, combining artemisinins with two c

99 Combination therapy consisting of gemcitabine and MN-siP

100 improvement than one alone, suggesting that combination therapies could be effective in RTT.

101 r, these data indicate that rhIL-15/avelumab combination therapy could be a useful strategy to enhanc

102 Patients treated with combination therapy demonstrated a rapid decline in para

103 Carbapenem-colistin combination therapy did not reduce the incidence of coli

104 ng BRAFi, aPDL1, and CSF1R-blocking antibody combination therapy did not show greater levels of TAM o

105 ates of treatment failure with the frontline combination therapy dihydroartemisinin-piperaquine.

106 y models - fissures impacting all aspects of combination therapy discovery and deployment.

107 rtemisinins or key partner drugs included in combination therapies does not appear to be a substantia

108 n lean mice, the additional weight loss from combination therapy does not improve cardiovascular para

109 agents, which in turn may inform ongoing LRA combination therapy efforts.

110 Undetectable MRD (uMRD) at end of combination therapy (EOCT) was associated with superior

111 Three distinct therapeutic modalities (combination therapies, ex-vivo gene therapy, and in-vivo

112 ch inhibit tumor growth alone, the effect of combination therapy exceeds that of either drug.

113 Biologic, thiopurine, or combination therapy exposure during pregnancy was not as

114 a together with new mutations and increasing combination therapy failures blow alarms for urgent mala

115 es, and a far richer array of PARP inhibitor combination therapies for BRCA1-deficient cancers than w

116 d middle-income countries (LMICs): optimised combination therapies for confirmed meningitis cases and

117 th newly diagnosed multiple myeloma includes combination therapies for patients who are not eligible

118 n can be used in development of immune-based combination therapies for PDAC.

119 R-15/16 expression, can lead to targeted and combination therapies for the treatment of this incurabl

120 d by the same organism are used in important combination therapies for treatment of drug-resistant ba

121 , which provides a strong rationale for this combination therapy for cancer patients.

122 nce the therapeutic efficacy of the proposed combination therapy for HCC.

123 was to assess the long-term effectiveness of combination therapy for intermittent claudication, compa

124 and future studies evaluating the impact of combination therapy for invasive MRSA infections.

125 and future studies evaluating the impact of combination therapy for invasive MRSA infections.Patient

126 a novel concept for intratumoral chemo-radio combination therapy for locally advanced solid tumors.

127 velopment as a partner drug of a single-dose combination therapy for malaria.

128 roved use of bedaquiline fumarate as part of combination therapy for multidrug-resistant tuberculosis

129 , anti-RANKL or bisphosphonates as potential combination therapy for PARP inhibitors.

130 an NBAT1-dependent CRM1/MDM2-based potential combination therapy for patients with high-risk neurobla

131 hese data do not support routine use of this combination therapy for patients with septic shock.

132 in vivo, presenting an effective, tolerated combination therapy for preventing progression of HK1(-)

133 d the use of bedaquiline fumarate as part of combination therapy for treatment of multidrug-resistant

134 odium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic re

135 treatment policy was changed to artemisinin combination therapy for uncomplicated malaria and intrav

136 exercise only group compared to that in the combination therapy group (65 versus 149).

137 d the 5-year study: 811 (81.3%) in the early combination therapy group and 787 (78.5%) in the monothe

138 larized mice were divided into 2 groups: the combination therapy group received FND cauterization and

139 blockade in clinical studies, especially in combination therapy groups, is a cause for concern.

140 as progression-free survival between the two combination-therapy groups, assessed by independent revi

141 The combination therapy had a manageable toxicity profile.

142 MRE+BIO combination therapy had additive protective effects on D

143 PD1 blockade-based combination therapy has been approved as a first-line tr

144 atment with all-oral direct-acting antiviral combination therapy has been associated with very high H

145 Combination therapy has long been applied to enhance the

146 Combination therapy has shown to improve therapeutic eff

147 tner drug, all recommended artemisinin-based combination therapies have shown reduced efficacy in som

148 nd we suggest that future efforts to develop combination therapies have the potential to be curative.

149 Combination therapies have the potential to improve pati

150 ssive agents, and especially those receiving combination therapy, have an impaired immune response co

151 ons, pentamidine and nifurtimox-eflornithine combination therapy, have been expanded to include fexin

152 onotherapies were additive in the context of combination therapy; however, multiple combination thera

153 regard to common clinical scenarios, such as combination therapy, ICI rechallenge and risk of relapse

154 SGLT-2i combination therapies improved glucose homeostasis, inde

155 after the policy change to artemisinin-based combination therapies in 2005, the pfcrt K76 and pfmdr1

156 ow assessment of novel anticancer agents and combination therapies in a veterinary clinical setting t

157 emergence of resistance to artemisinin-based combination therapies in Africa would probably have deva

158 ial to evaluate and improve standard-of-care combination therapies in cancer.

159 network methodology to identify efficacious combination therapies in drug development.

160 and/or efficacy-linking biomarkers for these combination therapies in patients with HER2+ breast canc

161 ming and further emphasizes the advantage of combination therapies in prolonging transplant survival.

162 odel for testing immunotherapy compounds and combination therapy in a preclinical setting.

163 itiation that is vulnerable to inhibition as combination therapy in cancer.

164 Non-inferiority of combination therapy in comparison to standard therapy al

165 clinical evaluation of CMP-001 and anti-PD-1 combination therapy in lymphoma will begin shortly, base

166 egrin signaling inhibition as a component of combination therapy in pancreatic cancer.

167 vity and safety of dabrafenib and trametinib combination therapy in patients with BRAF(V600E)-mutated

168 in these cells as a marker of sensitivity to combination therapy in resistant cells.

169 effective than constant-dose monotherapy or combination therapy in vitro.

170 pment have shown promise, either as mono- or combination therapy, in refractory and difficult-to-trea

171 ividual target antimicrobials and vancomycin combination therapies, including adjustment for known co

172 Additionally, combination therapy induced higher IFN-gamma production

173 Combination therapies involving metabolic inhibitors wit

174 Combination therapy is increasingly central to modern me

175 identified beta-lactamase inhibitors and of combination therapy is provided.

176 Building on a genetic mouse model, a novel combination therapy is uncovered that is relevant to hum

177 iparum clearance following artemisinin-based combination therapy), is widespread across Southeast Asi

178 Instead, combination therapy led to a significant decrease in imm

179 e pathway of resistance cannot be predicted, combination therapies may address this progression.

180 tumors, suggesting that the mechanism-based combination therapy may be an alternative approach to tr

181 EGF-C and -D was well tolerated, and OPT-302 combination therapy may overcome an escape mechanism to

182 These data suggest that this combination therapy may represent a novel strategy to ta

183 and 5.3 injections (5.0 monotherapy vs. 5.6 combination therapy; mean, 1.2 PDT sessions), respective

184 These observations suggest our novel combination therapy modifies macrophage polarization in

185 Among eyes with steroid and NSAID combination therapy (n = 55), CRT increased 3.6 +/- 4.1

186 We confirmed the efficacy of PI3K and EGFR combination therapies, observing synergy with alpha isof

187 c knowledge and potential clinical benefits, combination therapies of (223)Ra with microtubule-stabil

188 here that the two commonly used artemisinin combination therapies of artesunate plus amodiaquine and

189 o emerging antibiotic resistance may involve combination therapies of existing antibiotics and potent

190 optosis and ferroptosis in vitro and in vivo Combination therapies of SCD1 inhibitors and ferroptosis

191 Combination therapy of a HER2 inhibitor and an AKT inhib

192 h FOLR1-T-cell bispecific (TCB) antibody and combination therapy of CEA-TCB (RG7802) and CEA-targeted

193 In our case, the initial combination therapy of corticosteroids plus mesalazine f

194 Here, we propose that a combination therapy of current antiglioma regimens and a

195 The combination therapy of docetaxel and C3 receptor antagon

196 Combination therapy of papilla preservation, connective

197 Combination therapy of steroids and NSAIDs had no added

198 Treatment with combination therapy of steroids and NSAIDs showed no add

199 and ELA to compare the effects of mono- and combination therapies on metabolic and histological endp

200 Combination therapy or longer treatment duration may be

201 mg of moxidectin plus 400 mg of albendazole combination therapy; or placebo.

202 BA)/long-acting muscarinic antagonist (LAMA) combination therapy over LABA or LAMA monotherapy in pat

203 (MAX) = 2.2 hr and T(1/2) = 4.7 hr), and two combination therapy protocols including drugs with simil

204 ons for clinical translation of the proposed combination therapy, providing a safe and affordable str

205 We evaluated whether carbapenem-colistin combination therapy reduces the emergence of colistin re

206 asis for future work aimed at developing new combination therapy regimens that target multiple pathwa

207 , mechanisms underlying the efficacy of this combination therapy remain unclear.

208 Nifurtimox-eflornithine combination therapy remains recommended for patients wit

209 none were associated with artemisinin-based combination therapy resistance.

210 gMAR letters (P < 0.001) for monotherapy and combination therapy, respectively.

211 pharmacological intervention, as part of CF combination therapies restoring Phe508del-CFTR function.

212 Combination therapy resulted in a lower number of revasc

213 BRAFi and aPDL1 combination therapy resulted in higher tumor DDNP delive

214 is experimental data and determine if DAP+BL combination therapy results in improved clinical outcome

215 se experimental data and determine if DAP+BL combination therapy results in improved clinical outcome

216 ate important opportunities for image-guided combination therapy.See related article by Ghosh et al.,

217 to develop a framework for biomarker-driven combination therapy selection.

218 d studies on second-generation antipsychotic combination therapies (SGAs) (i.e., aripiprazole, lurasi

219 -acting beta (2)-adrenoceptor agonist (LABA) combination therapy should be a first-in-line treatment

220 The combination therapy showed acceptable safety and tolerab

221 This combination therapy showed preliminary antitumour activi

222 Furthermore, this combination therapy showed significant abscopal effect o

223 gs might pave a way for new synthetic lethal combination therapies.Significance: These findings highl

224 onducted to assess the benefits of TRT-based combination therapies, sometimes despite limited preclin

225 xt of combination therapy; however, multiple combination therapy-specific effects were observed.

226 Triple artemisinin-based combination therapies (TACTs), which combine existing co

227 ffers an innovative strategy for identifying combination therapies tailored to the oligoclonal landsc

228 NLRP3 inflammasomes for CNV and suggest that combination therapies targeting inflammasomes and comple

229 our 3D co-culture model, we discovered that combination therapies targeting oxidative phosphorylatio

230 dencies" (CDs) and identified two classes of combination therapies targeting these CDs that increased

231 lycoprotein, and the findings suggest that a combination therapy targeting both F and G should be eva

232 To delay or prevent resistance, combination therapy targeting BRAF and MEK, a downstream

233 help combat antifungal resistance, including combination therapy, targeting fungal-virulence traits,

234 imately 5.8 mm Hg with the polypill and with combination therapy than with placebo.

235 biology of resistance and to identify novel combination therapies that are effective against resista

236 rs of response to immunotherapy and rational combination therapies that can enhance efficacy by overc

237 ngs of c-MET inhibition and identified novel combination therapies that may enhance its therapeutic e

238 otherapy and thus are relevant to developing combination therapies that target distinct T cell functi

239 establish a paradigm for the development of combination therapies that target OXPHOS and glycolysis.

240 ce among the five drugs comprising R-CHOP, a combination therapy that frequently cures Diffuse Large

241 istance mutations have emerged in first-line combination therapy that includes the integrase strand t

242 ression and identified a novel pharmacologic combination therapy that interferes with PAX3-FOXO1 biol

243 compound for development of new antimalarial combination therapy that retains activity against artemi

244 when combined with immunomodulatory drugs, a combination therapy the authors term electroimmunotherap

245 insecticide-treated bed nets and artemisinin combination therapy, the threat of drug resistance is a

246 cilitating the discovery of more efficacious combination therapies to block drug-tolerant cells.

247 This suggests the need for novel combination therapies to expand the use of these drugs.

248 the development of rational synergistic RLT-combination therapies to improve outcomes for PCa patien

249 blast-rich tumors and the design of rational combination therapies to restore drug sensitivity.

250 hes and build further mathematical models of combination therapies to treat prostate cancer and CRPC.

251 be administered individually or utilized in combination therapy to augment the effects of current an

252 omarkers to ICB therapy and guide the use of combination therapy to further boost the antitumor effic

253 ighlight potential clinical strategies using combination therapy to overcome the limitations associat

254 ensitivity to BRAFi-resistant tumors or as a combination therapy to prevent the onset of drug resista

255 the oncogenic protein YAP1 and identifies a combination therapy to target these pathways in the chil

256 unders (age, comorbidities, steroid use, and combination therapy) to determine the association betwee

257 nt considerations and management of selected combination therapy toxicities.

258 ubsequently throughout 48 weeks of NAP-based combination therapy (treatment weeks 24-72 in the experi

259 sed HCC-related cytokines, (2) UTMD-microRNA combination therapy triggered transient cytokine storms,

260 h blocker Abs in two mouse tumor models, and combination therapy using both classes of Abs enhanced t

261 to highlight the advances in research about combination therapy using conventional therapeutics and

262 Combination therapy using fluoxazolevir and daclatasvir

263 tudy, we assessed the safety and efficacy of combination therapy using liposomal amphotericin B (LAmB

264 Long-term follow up after combination therapy versus supervised exercise only, dem

265 For the combination therapy vs standard therapy groups, all-caus

266 The RP2D for combination therapy was M6620 90 mg/m(2) with carboplati

267 Combination therapy was more commonly used in polymyxin/

268 Intensification with noninsulin combination therapy was slower in both nonwhite ethnic g

269 Cefazolin and ertapenem combination therapy was used successfully to salvage 11

270 he efficacy of twenty-eight dual beta-lactam combination therapies were compared to their constituent

271 Our approach enables the prediction of combination-therapy which can be linked to tumor-driving

272 observed in patients treated with adalimumab combination therapy who did not carry HLA-DQA1*05.

273 standard practice and access to personalized combination therapy will be critical if childhood cancer

274 nd that anti-adhesion-antibiotic-debridement combination therapy will be more effective than any of t

275 high ploidy as a prerequisite to personalize combination therapies with cytotoxic drugs and inhibitor

276 s, and discuss improved delivery methods and combination therapies with other antiviral drugs.

277 These observations suggest that combination therapy with a cystine-depleting drug such a

278 Combination therapy with anti-PD-1 antibody further acce

279 S cells grown from 15 human tumors show that combination therapy with AZD2014 and dasatinib is more e

280 Yet, combination therapy with CD40 agonist and Flt3 ligand re

281 ch as HER2, and developing blocking antibody-combination therapy with chemotherapies or radiotherapy.

282 of DAC in the original KPC model and tested combination therapy with DAC followed by immune checkpoi

283 may be important to enhance the efficacy of combination therapy with DAC plus ICI.

284 ; median 10 [IQR 7-13]), 36 of whom received combination therapy with dose escalation, with a median

285 Combination therapy with drugs able to safely induce NQO

286 The efficacy and safety of combination therapy with eflornithine and sulindac, as c

287 as a potential new target for monotherapy or combination therapy with established chemotherapeutics t

288 P technology can be a suitable candidate for combination therapy with existing chemotherapeutic drugs

289 ficacy and safety of biologic monotherapy vs combination therapy with immunomodulators, (3) comparati

290 To evaluate if a combination therapy with micropulse diode laser (MPL) sh

291 nti-PD-1, strengthening the rationale behind combination therapy with oncolytic viruses.

292 on exposure to normal organs was low, making combination therapy with other anticancer therapies feas

293 Combination therapy with Ox/Cy and anti-PD-L1 synergisti

294 ast, for PCV eyes, anti-VEGF monotherapy and combination therapy with PDT yielded comparable outcomes

295 Combination therapy with pyridostigmine and salbutamol c

296 quired cetuximab resistance of OSCC and that combination therapy with resveratrol may provide an attr

297 Combination therapy with small-molecule inhibitors of AK

298 veness of targeting parasite-produced MIF as combination therapy with standard antibiotics to reduce

299 emonstrated in vitro and in vivo efficacy of combination therapy with the dual mTORC1/2 inhibitor AZD

300 se II (TOP2) poisons can be enhanced through combination therapy with ubiquitin-activating enzyme inh